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Endogenous vs Exogenous 
Allosteric Modulators in GPCRs: 
A dispute for shuttling CB1 
among different membrane 
microenvironments
Mariano Stornaiuolo1,*, Agostino Bruno1,*, Lorenzo Botta1, Giuseppe La Regina2, 
Sandro Cosconati3, Romano Silvestri2, Luciana Marinelli1 & Ettore Novellino1
A Cannabinoid Receptor 1 (CB1) binding site for the selective allosteric modulator ORG27569 is 
here identified through an integrate approach of consensus pocket prediction, mutagenesis studies 
and Mass Spectrometry. This unprecedented ORG27569 pocket presents the structural features 
of a Cholesterol Consensus Motif, a cholesterol interacting region already found in other GPCRs. 
ORG27569 and cholesterol affects oppositely CB1 affinity for orthosteric ligands. Moreover, the 
rise in cholesterol intracellular level results in CB1 trafficking to the axonal region of neuronal cells, 
while, on the contrary, ORG27568 binding induces CB1 enrichment at the soma. This control of 
receptor migration among functionally different membrane regions of the cell further contributes to 
downstream signalling and adds a previously unknown mechanism underpinning CB1 modulation by 
ORG27569 , that goes beyond a mere control of receptor affinity for orthosteric ligands.
The endocannabinoid system comprises the GPCR family members cannabinoid receptors CB1 and CB2, 
their endogenous ligands (endocannabinoids) and the enzymes responsible for the synthesis and deg-
radation of the latters1. Upon binding to their endogenous partial agonist anandamide or to exogenous 
ligands like Δ 9-tetrahydrocannabinol, CB1 affects cell proliferation, motility, adhesion and apoptosis and 
controls a variety of physiological processes spanning from neuronal development to organs function-
ing2,3. Signalling by CB1 involves both G protein-dependent pathways, such as inhibition of adenylate 
cyclase, as well as G-protein independent mechanisms4–6. Due to its widespread distribution7 and impli-
cation in many diseases CB1 is ranked among the golden targets for the treatment of nausea, obesity, 
pain, neurodegenerative diseases and substance abuse disorders8.
GPCRs orthosteric binding sites have been extensively investigated to identify new ligands. Three CB1 
ligands (Cesamet9, Marinol10, and Sativex11) are being prescribed to reduce chemotherapy-induced nau-
sea, stimulate appetite or reduce pain8. On the contrary, the CB1 inverse agonist rimonabant was initially 
commercialized as anorectic antiobesity drug and then suspended due to its psychiatric side-effects12. Its 
withdrawal pointed out the risk of targeting GPCRs orthosteric sites, highly conserved among GPCRs13.
Alternative approaches for GPCRs drug discovery are thus being considered in order to develop safer 
drugs and achieve a better fine-tuning of GPCR functionality14. While orthosteric sites have faced high 
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evolutionary pressure in order to keep an efficient binding to their endogenous ligands, the evolution of 
allosteric pockets has been less stringent causing their aminoacidic sequences to be poorly conserved and, 
as consequence, more specific for each receptor15. The development of functionally selective allosteric 
modulators is thus considered a promising avenue to develop new target specific drugs and overcome 
nowadays obstacles in cannabinoid-based drug discovery such as on- and off-target side effects.
To date, few compounds have been identified as exogenous CB1 allosteric modulators including the 
synthetic “ORG” compounds (ORG27569, ORG29647, ORG27759)16,17, PSNCBAM-118, RTI-37119 and 
the natural endogenous modulators lipoxin A420, pregnenolone21 and cholesterol22. Recently our group 
embarked in a Structure-Activity-Relationship (SAR) study of ORG2756923 which is an exquisitely selec-
tive allosteric modulator for CB123,24.
Despite positively affecting CB1 affinity for some agonists, ORG compounds inhibit agonist-induced 
G-protein coupling. Independently from the CB1 orthosteric site being occupied or not, ORG27569 selec-
tively hampers G-protein signalling and promotes β -arrestin2-mediated internalization of the receptor 
and β -arrestin1-mediated activation of kinases17,25. However, the mechanism behind CB1-biased signal-
ling by allosteric ligands remains still obscure as well as the molecular basis of its selectivity over CB2. 
Furthermore, the missing identification of its binding site hampers a structure-based evolution towards 
new ORG27569-inspired allosteric molecules. Recently, a site partially overlapping with the CB1 ortho-
steric site has been proposed as binding pocket for ORG2756926. However, the proof of such hypothesis 
was based on a comparison between the functional activity of the wt receptor and that of mutants at the 
proposed binding site, while no data were shown on the effect of such mutations on the binding proper-
ties of the receptor26. Moreover the existence of a competition between ORG27569 and inverse agonists 
for the same binding site, corollary of that hypothesis, is not in line with the data proving the inability 
of the allosteric molecule to physically displace orthosteric ligands24,27.
Herein, through a multidisciplinary approach we physically identify an ORG27569 binding site. 
Interestingly, this site presents structural features of a CCM (Cholesterol Consensus Motif), a choles-
terol binding region that have already been identified in other GPCRs28. Advanced Molecular Dynamics 
(MD), here presented, suggest ORG27569 binding mode and CB1 structural changes upon allosteric 
ligand binding. In cultured cells we show that, while cholesterol allows enrichment of CB1 at the axon, 
where endocannabioid pathway effectors are mainly localized29, ORG27569 drives CB1 close to the soma. 
This proves that the ORG27569 allosteric modulation works at least on two levels: i) by fine tuning 
receptor affinity for orthosteric ligands and ii) by topologically control of CB1 membrane localization.
Results
Prediction of ORG27569 candidate Binding Sites and selection of mutants. Consensus pocket 
prediction on the entire CB1 receptor was performed to identify ORG27569 candidate binding sites. 
Beside the canonical orthosteric pocket, nine potential allosteric sites were identified (See Computational 
Protocol and Supplementary Fig. S1–3). Since ORG27569 selectively binds CB1 over CB223,24, we only 
selected pockets presenting at least one aminoacidic difference between CB1 and CB2. Thus, only five 
potential binding sites (P1-5) for ORG27569 were further considered (Fig.  1a). With the exception of 
pocket 4 (P4), which partially overlaps with the orthosteric pocket, the other sites are all lipid exposed 
(Fig.  1a). Noteworthy, P1, P2, and P4 were previously reported as putative allosteric pocket for other 
GPCRs28,30,31. For each candidate site only 3 residues (not conserved in CB2) were considered for site-di-
rected mutagenesis (Table  1). These were mutated in the corresponding CB2 residues rather than in 
Alanines, to avoid non-functional mutant receptors (see Supplementary Fig. S4 for details).
Screening of CB1 Mutants toward ORG27569 binding pocket identification. 15 CB1 mutants 
(Table 1), each carrying one CB1 residue substituted with the corresponding CB2 counterpart were gen-
erated. ORG27569 binding site was identified by testing each CB1 mutant in a two steps pipeline: first 
we i) excluded mutations abolishing binding to an orthosteric inverse agonist; then ii) we selected those 
mutants which affinity for orthosteric ligands was unaffected by ORG27569 treatment. As tool for the 
pipeline, we used a newly developed assay based on T1117, a fluorescently labeled analogue of rimon-
abant. We recently proved that upon binding to CB1, T1117 gets fluorescently quenched and that its 
change in fluorescence relates to the affinity of CB1 for orthosteric and allosteric molecules32. T1117 
specifically bound to CB1wt was efficiently measured by displacement with the CB1 specific orthosteric 
ligand AM25132. Six of the CB1 mutants tested (Fig. 1b) made the CB1 receptor unable to bind the ortho-
steric ligand, thus they were tossed out. P4 partially overlaps with the T1117 binding site32 and T7.33, even 
if not being in direct contact with T1117, locates at the entry portal of the ligand into the orthosteric 
binding site32. Mutations on TM3 (where A3.34 is located) were already shown to negatively influence 
AM251 binding17 and those in the surroundings of P1 are known to abolish CB1 conformational changes 
linked to G protein activation and thus they could likely affect orthosteric binding.
The nine CB1 mutants still able to bind T1117 (Fig. 1b,c) moved to the second step of the pipeline. 
The binding of CB1wt to T1117 is negatively affected by ORG27569 treatment (IC50 = 3.0 μ M)24,32. On the 
contrary, the three mutants C1.55Y, H2.41L and F4.46L, strikingly all belonging to the same P2 pocket, were 
completely unaffected by ORG27569, with the allosteric molecule decreasing their binding to T1117 only 
of a 0–10% (Fig. 1c). Mutations in pocket P3, P4 and P5 reduced the susceptibility of probe binding to 
ORG27569 to a lesser extent (Fig. 1c). Interesting is the effect of two mutations in the P1 pocket, where 
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Figure 1. ORG27569 pocket identification. (a) The 5 putative allosteric pockets mapped onto the CB1 
homology model. Probes identifying each site are represented by differently colored surfaces. The three 
mutated residues for each site are highlighted in colored sticks. P1 is defined by TM1-TM7 and H8 domains, 
P2 by TM1-4, P3 by the same TM domains of P2 but towards the extracellular region, P4 is defined by 
residues on TM3 and TM7, finally P5 is defined by TM3-5. (b) Human CB1wt receptor and the indicated 
CB1 mutants were transiently expressed in HEK293 cells. Membrane homogenates were obtained and T1117 
binding measurement performed as described in the On line Method Sections. Specific binding correlates 
with the fold change increase of T1117 fluorescence in presence of AM251. (c) Membrane homogenates 
were obtained from cells expressing CB1wt receptor or the indicated CB1 mutants. Samples were incubated 
with ORG27569 (3 μ M) for 30 minutes. T1117 specific binding measurement was performed as described 
above. Effect of ORG27569 treatment is expressed as change in T1117 specific binding upon ORG27569 
treatment ( for panels b and c the data depict the mean + /− s.e.m. and are representative of three or more 
independent experiments. P < 0.05. ANOVA-test was employed). (d) Peptides identified by LC/MS analysis 
and presenting ORG27569alk3 covalently linked to S2.45 or to S3.42 of the P2 pocket. Peptide abundance 
is plotted as a function of mass/charge (m/z). Amino acids that could present ORG27569alk3 covalently 
bound are shown in red. The inset shows the region addressed by the probe (red, surface) superimposed 
with the P2 binding pocket (cyan, surface); (e) rat CB1wt-GFP and CB1(H2.41L)-GFP constructs were 
transiently expressed in HuH7 (upper panels) and SHSY-5Y (lower panels) that were treated (+ ORG27569) 
or not (ctrl) with ORG27569 (3 μ M) for 4 hours (see also Supplementary Fig. S6).
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one (I7.51V) decreases susceptibility to ORG27569 to 70%, while another (F8.54A) increases the same of 
30% (Fig.  1c). The effect of F8.54A mutation on P1 became clearer after experiments described below. 
Thus, in vitro binding measurements clearly suggest that, among the five pockets tested, P2 is a binding 
site for ORG27569.
Identification of the binding site of an ORG27569-derived probe by Liquid Chromatography/
Mass Spectrometry. To confirm ORG27569 addressing the P2 pocket, we converted the allosteric 
ligand in a molecular probe by derivatization with an alkyne moiety. Despite being extremely unreactive, 
alkynes can receive nucleophilic attacks from sulfhydryl or hydroxyl group of amino acids to generate 
covalent adducts. This extremely rare event has been shown to happen at catalytic sites of enzymes as 
well as in ligand binding pockets33.
We attempted derivatization of ORG27569 at 4 different positions (ORG27569alk1-4, See Chemistry 
section in the Supplementary Information). ORG27569alk 1 and 2 were strongly insoluble and thus 
could not be used. ORG27569alk4 induced massive cell detachment in within 1 hour from the treat-
ment. On the contrary, ORG27569alk3 was well tolerated by the cells and thus was used as candidate 
probe.
CB1-GFP expressing HEK293 cells were cultured in the presence of ORG27569alk3. After the 
treatment, CB1-GFP was immunopurified, digested with Proteinase K and analyzed by Liquid 
Chromatography/Mass Spectrometry (LC/MS). HPLC profiles of samples from ORG27569alk3 treated 
cells and untreated ones were compared. These were almost totally overlapping with the exception of i) 
a fraction eluting with retention time of 14.0 min presenting the unbound probe (Supplementary Fig. 
S5) and ii) a fraction eluting with retention time of 3.8 min and present only in samples obtained from 
ORG27569alk3 treated cells (Supplementary Fig. S5). The peptide eluting in this fraction presents a m/z 
of 723.7 Da and corresponds, with a deviation from theoretical mass (Δ mass) of 0.2 Da, to the sequence 
GSL (amminoacids 158–160 or 206–208) of CB1 (theoretical mass of the peptide 276.1 Da) presenting 
ORG27569alk3 ( MW = 447.8 Da) covalently linked either to S2.45 or to S3.42 (Fig. 1d) (theoretical mass 
[M-H-ORG27569alk3]+ of 723.9 Da). Despite the presence of nucleophilic Ser, Thr, Tyr and Cys present 
in the other investigated pockets (Supplementary Fig. S5), the spectra clearly indicate ORG27569alk3 
is addressing the P2 pocket, with it contacting at least S2.45 or S3.42, which both belong to P2 pocket and 
are in close proximity to each other (Fig. 1d).
Effect of H2.41L mutation on CB1 intracellular localization. To finalize our ORG27569 binding 
pocket identification the intracellular distribution of the H2.41L mutant (P2) was followed in cultured 
cells. The mutant H2.41L was generated on the template of a C-terminally tagged GFP version of the rat 
wt receptor34. When expressed in Human Hepatoma Cells (HuH7), CB1wt-GFP appears mainly localized 
on the cells Plasma Membrane (PM) and in intracellular vesicles, similarly to what was already seen 
in many other cell type34 (Fig.  1d and supplementary Fig. S6). Upon treatment with ORG27569, the 
intracellular pool of CB1wt-GFP increased as already reported17,24,25,27. CB1(H2.41L)-GFP localizes at the 
Mutation List
Pocket
Residue Exchange
Position CB1 CB2 Mutation
P1
1.45 Phe Leu F1.45L
7.51 Ile Val I7.51V
8.54 Phe Ala F8.54A
P2
1.55 Cys Tyr C1.55Y
2.41 His Leu H2.41L
4.46 Phe Leu F4.46L
P3
3.27 Phe Leu F3.27L
3.34 Ala Met A3.34M
4.54 Ile Ala I4.54A
P4
3.29 Leu Ile L3.29I
6.58 Asp Ser D6.58S
7.33 Thr Lys T7.33K
P5
4.52 Ile Leu I4.52L
4.56 Ile Val I4.56V
5.46 Val Phe V5.46F
Table 1.  List of the generated CB1 mutants.
www.nature.com/scientificreports/
5Scientific RepoRts | 5:15453 | DOi: 10.1038/srep15453
steady state at the PM and in intracellular vesicle like the CB1wt protein, on the contrary the treatment 
with ORG27569 does not alter its localization (Fig. 1e and Supplementary Fig. S6). This data indicates 
that CB1(H2.41L)-GFP is correctly folded and transported to its final localization, but that it is not able to 
bind ORG27569, confirming our previous data indicating that P2 is a recognition pocket of ORG27569.
Finally, the CB1wt-GFP and the CB1(H2.41L)-GFP mutant were both expressed in cells of neuronal 
origin, that more closely resemble the natural context where CB1 is endogenously expressed. In untreated 
SHSY-5Y neuroblastoma cells, CB1wt-GFP appears mainly localized on the PM of the cells equally distrib-
uted among dendrites/axons and central body (Fig. 1e). Noteworthy, 4 hours treatment with ORG27569 
moved the pool of CB1wt-GFP in intracellular vesicles, while CB1(H2.41L)-GFP resulted completely unaf-
fected by the treatment (Fig. 1e). All together these data indicate that CB1(H2.41L)-GFP is not sensitive 
to the treatment with ORG27569 in vitro as well as in cultured neuronal and non neuronal cell lines. 
Moreover, the affinity for T1117 and the PM localization of CB1(H2.41L)-GFP indicates that the mutant 
is correctly folded and transported along the secretory pathway. Taken together these data confirmed P2 
as an allosteric site of ORG27569 within the CB1 receptor.
Theoretical predictions of CB1 structural changes upon ORG27569 binding. Docking of 
ORG27569, by means of Glide software, was focused on P2 pocket and resulted in a binding mode (Fig. 2a) 
in line with the reported SAR35 (see the Binding mode reliability section in the Supplementary Information), 
the mutagenesis data (Figs 1c–e and 2a), and the CB1/CB2 selectivity profile23,24. Both H2.41 and F4.46 directly 
participate in ORG27569 binding and, together with V2.48 are not conserved in CB2. We did not observe a 
direct interaction between ORG27569 and C1.55, thus it might be conceivable that the introduction of the 
bulkier tyrosine (C1.55Y substitution) could hamper the ligand entry into the P2 pocket.
To support our docking-derived pose of  ORG27569 and to unravel the local receptor structural 
changes upon its binding, extensive MD simulations for the unbound CB1wt, CB1wt-ORG27569 and 
CB1-(H2.41L)-ORG27569 complexes were performed as follows: (i) for the CB1wt system, three 1 μ s MD 
simulations in explicit POPC:Chol 2:1, POPC:Chol 2:1 at 310K, and DOPC:Chol 2:1 membrane envi-
ronment were performed; (ii) for the CB1wt-ORG27569 system two 1 μ s MD simulations, in POPC:Chol 
2:1, starting from different binding conformations, were carried out; (iii) for the CB1-(H2.41L)-ORG27569 
system, a 1 μ s MD simulation long was performed in POPC:Chol 2:1.
Along all the trajectories, the CB1wt-ORG27569 simulations revealed the docking-derived binding 
mode being highly stable (See Supplementary Fig. S7). On the contrary, in the CB1-H2.41L dynam-
ics, a substantial fluctuation of ORG27569 was appreciable, accordingly with mutagenesis data (See 
Supplementary Fig. S7). In the attempt to comprehend the CB1 structural changes upon allosteric 
ligand binding, a comparison between the CB1wt and the CB1wt-ORG27569 simulations was performed 
(Fig.  2b–e) and revealed that ORG27569 binding could cause an H-bond loss between the H2.41 Nε 
(TM2) and the R148 backbone oxygen (ICL1, Fig. 2b,c and Supplementary Fig. S8). Thus, by weakening 
the TM2/ICL1 interactions the allosteric ligand could allow a ICL1 rearrangement and eventually pro-
mote the formation of a salt bridge between R150 (ICL1) and D8.49 (H8) (Fig. 2a–d and Supplementary 
Fig. S8 and S9). This confirms previously published results showing H8 and ICL1 domains implicated in 
G-protein coupling or receptor internalization, in CB136,37 as well as in other GPCR such as Rhodopsin38, 
or α 2A-adrenergic receptor39. Noteworthy, these observations were statistically supported by all the MD 
simulations carried out in different conditions as above introduced (See Supplementary Fig. S8 and S9).
Upon ORG27569 binding, a pronounced displacement of the TM3 C-terminus region was observed 
at the T3.46 level (Fig.  2e and Supplementary Fig. S10), which has been implicated in the so called 
Hydrophobic Hindering Mechanism (HHM), in CB1 and other GPCRs17,40,41, supporting the idea that 
the alteration of this region, by the presence of ORG27569, may affect the orthosteric ligand binding 
affinity through the TM3 displacement.
Three-dimensional superposition of all the GPCR X-ray structures disclosed so far (See Supplementary 
Fig. S11) revealed that, the herein identified CB1 site (P2 site) corresponds to a CCM, a sequence shown 
to be sufficient to dictate cholesterol binding in many GPCRs28. When we analyzed the unbound CB1 
dynamics in the three explicit membrane conditions (see Methods and Supplementary Fig. S12) several 
cholesterol molecules were found interacting with different domains of the CB1 receptor, as expected, 
(Fig. 2f and Supplementary Fig. S12). Interestingly one of them was actually found accommodated in the 
P2 cleft (Fig. 2g,h and Supplementary Fig. S12) adopting a binding conformation similar to that observed 
in the CCM pocket of other GPCR X-ray structures (See Supplementary Fig. S13)28.
The aforementioned observations suggested an intriguing scenario, for which change in cholesterol con-
centration and membrane composition could affect ORG27569 binding and even functionally compete 
with it.
Functional competition between ORG27569 and cholesterol modulates CB1 affinity for 
inverse agonist. Cholesterol has been shown to affect GPCRs either directly, by binding to them and 
affecting their conformation, or indirectly, by influencing the membranous environment in which they 
are embedded. Effect of cholesterol and its precursor pregnenolone on CB1 binding was already demon-
strated, with the lipids increasing the affinity of the receptor for inverse agonists21,22. We started proving 
that depletion of cholesterol, similarly to ORG27569, reduces CB1 affinity for T1117 (Fig. 3a,b). Rat brain 
membranes were treated or not with methyl-β -cyclodextrin (Mβ D) to selectively extract cholesterol and 
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Figure 2. ORG27569 and cholesterol binding mode. (a) ORG27569 Binding mode. Key interactions 
included: (i) two H-bonds established by the 1H-indole-2-carboxamide group with the H2.41 Nδ atom and 
the S2.45 side chain; (ii) the 1-(4-ethylphenyl)piperidine arm accommodating in a hydrophobic region 
interacts with F4.46, V2.48, L1.54, and L1.58; and (iii) the 3-ethyl group plunges through a hydrophobic area 
establishing contacts with L3.45 and M4.49. (b) H2.41 x1 and x2 dihedral angles distribution for the CB1wt-
ORG27569 simulation (run 1). The probability of each state was normalized. A highly represented 
conformer, in the CB1wt-ORG27569 MD, for the H2.41 residue (conformer 2), different from that observed 
in the CB1wt unbound state (conformer 1, see also Supplementary Fig. S9) was noticed. Remarkably, in 
the CB1wt-ORG27569 simulations, the shift from H2.41 conformer 1 to 2 causes the H-bond loss between 
the H2.41 Nε (TM2) and the R148 backbone oxygen (ICL1, Fig. 2d). (c–e) Probability distribution for the 
H2.41(NHε )-R148(O), F2.42(Cα )-T3.46(Cα ), and R150(CZ)-D8.49(CG) distance atoms, for CB1wt (blue lines) 
and the CB1wt-ORG27569 simulations (black , and red lines), respectively. The probability of each distance 
was normalized. (f) Probability distribution of cholesterol molecules along the x and y axes with respect to 
the main axis of CB1, only cholesterol molecule into the lower leaflet of the bilayer were considered (See 
Appendix A in Supplementary Information for a detailed description of the calculation of the probability 
distribution). (g) Probability distribution of the cholesterol molecule, which binds to the CCM during the 
CB1wt POPC:Chol (2:1) simulations. The probability distribution distance for the W4.50(Cα )-CHL(C13) 
carbon atoms (x axis) is plotted vs. the probability distribution distance for the NH(Arg148)-O atoms (y 
axis). (h) Binding mode of the cholesterol molecules in P2/CCM. The cholesterol molecule interacts with 
L1.54, L1.58, H2.41, V2.48, L2.52, F4.46, and W4.50 residues, while the R148 side chain anchors the OH apical group.
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thus T1117 binding was measured. Treatment with Mβ D (98–99% of total cholesterol extracted) drasti-
cally reduced T1117 binding. The loss of affinity for T1117 is indeed due to cholesterol withdrawal since 
the exogenous replenishment of cholesterol (50–70% of total cholesterol re-uptake) recovered the ability 
to bind the inverse agonist (Fig. 3a). This suggests that, in absence of cholesterol, the conformation of 
CB1 is less prone to bind the inverse agonist T1117.
The IC50 of ORG27569 for CB1 was then measured in cholesterol depleted membranes. After Mβ D 
treatment or cholesterol replenishment, membranes were incubated with increasing concentration of 
ORG27569. T1117 specific binding and IC50 for ORG27569 were then measured (Fig.  3b). As already 
seen before (Fig. 3a), upon Mβ D treatment, the total amount of T1117 bound to the CB1 was reduced. 
Moreover, in the absence of cholesterol, ORG27569 shows a threefold lower IC50 if compared to that 
obtained with untreated membranes (900 nM and 3.1 μ M, respectively). When Mβ D treated membranes 
were replenished with cholesterol, CB1 re-gained the ability to bind T1117, and ORG27569 IC50 rose in 
the high micromolar range (Fig. 3b). Thus, on rat brain membranes, cholesterol increases the binding of 
the inverse agonist (T1117) while decreases the IC50 of ORG27569.
Functional competition between ORG27569 and cholesterol influences CB1 distribution at 
Plasma Membrane. The effects of competition between ORG27569 and cholesterol were analyzed 
in cultured cells by following CB1 intracellular localization (Fig.  4). As already shown, upon agonist 
treatment, CB1 rapidly moves from the axons/dendrites to the neuron soma42 where endocytosis via 
chlatrin coated vesicles and receptor recycling occur. CB1 diffusion between axons/dendrites and soma 
was shown to be essential for its function43. We thus decided to follow change in CB1 localization in 
neurons upon ORG27569 treatment. After short treatment (30 minutes) with the allosteric molecule, the 
endogenous CB1 moved from axons to the cell soma (Fig. 4a), similarly to what has been reported after 
agonist treatment42. Noteworthy, longer treatment with ORG27569 (4 hours) induced the internalization 
of CB1. The effect of treatment with ORG27569 was specific for CB1 since neither CB1(H2.41L)-GFP or 
CB2 changed their localization after treatment with the allosteric molecule (Fig. 4b).
We thus subjected neuronal cells, treated with Mβ D and replenished or not with cholesterol, to short 
and long ORG27569 treatment. Similarly to ORG27569 treatment, when cholesterol was depleted by 
Mβ D (100% of cholesterol extracted), CB1 moved from dendrites to the central body of the neuron 
(Fig. 4a). This change in localization was reverted by cholesterol replenishment (70% of strarting choles-
terol re-uptake), after which CB1 localization moved back to the dendrites. In the absence of cholesterol, 
the endocitosis induced by ORG27569 was accelerated being visible already after 30 minutes of incuba-
tion with the allosteric molecule (Fig. 4a). However enrichment of CB1 in the lysosome was somehow 
delayed compared to undepleted cells treated with ORG27569, probably for the effect, already postulated, 
that severe cholesterol depletion has on the endosomal-lysosomal route34. On contrary, in cell replen-
ished with cholesterol incubation with ORG27569 did not induce CB1 internalization confirming that the 
Figure 3. Functional competition between ORG27569 and cholesterol. (a) Rat brain membranes were 
left untreated (blue bar) or were cholesterol depleted by treatement with Mβ C (10 mM, 15 minutes) to be 
then replenished (red bar) or not (green bar) with soluble cholesterol (1 mM, 15 minutes). In each bar is 
indicated the amount cholesterol measured in the membranes after each treatment ( expressed as % of the 
amount present in untreated samples, see methods for details). T1117 binding measurement performed as 
described in Fig.1b. Specific binding is indicated (data depict the mean + /− s.e.m. and are representative 
of 4 independent experiments. P < 0.05. One-way ANOVA-test was employed). (b) Rat brain membranes 
were treated with Mβ C and then replenished or not with cholesterol as described above. Membranes 
were incubated with the indicated amount of ORG27569. T1117 (2.5 μ M) was then added and specific 
binding measured as described in Fig. 1b. Data were fitted with a dose response curve as described in the 
Method Sections. (data depict the mean + /− s.e.m. and are representative of three or more independent 
experiments. One-way ANOVA was employed. P < 0.05).
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two molecules compete (Fig. 4a) influencing the topological distribution of CB1 between two functionally 
different regions of neurons the axonal/dendrites part and the soma of the neurons.
Discussion
A consensus pocket prediction on the entire CB1 receptor revealed nine potential allosteric sites. On 
the basis that ORG27569 selectively binds CB1 over CB223,24, and through mutagenesis experiments, we 
identified P2 as a ORG27569 binding site. ORG27569alk3, a derivatized version of the allosteric ligand, 
physically interacted with P2 addressing S2.45 or S3.42 (Fig.  1). In silico simulations were performed to 
reveal the ORG27569 binding mode and the CB1 structural changes upon allosteric binding. The simula-
tions strongly suggested that the ORG27569 binding elicits a TM3 displacement. This could be one of the 
major factor affecting the orthosteric agonist CP55940 binding affinity, in line with the observation that 
T3.46I mutation in CB1 as well as mutations on TM3, such as the L3.29I and A3.34M mutants here made, do 
affect the orthosteric site. In addition, upon binding of ORG27569, a H8-ICL1 rearrangement occurs (See 
Figure 4. ORG27569 and cholesterol dependent shuttling of CB1 among axons and soma of the neurons. 
SHSY-5Y were treated with Mβ C and replenished or not with cholesterol. After cholesterol manipulation 
cells were treated or not with ORG27569 (3 μ M) for the indicated time. After being fixed and permeabilized, 
cells were processed for immunfluorescence to detect endogenous CB1 receptor (panel (a)), endogenous 
CB2 (panel (b)) or transiently expressed CB1-H2.41L-GFP (panel (b)). White arrows and red arrows indicate 
axonal region and soma of the cell, respectively.
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Supplementary Fig. S8 and S9), and accordingly to already published experimental data36,37, this could 
explain the ORG27569 effect in blocking the CB1 coupling to its cognate G-protein.
A detailed analysis of the localization of allosteric pockets in other Class A GPCRs revealed that 
CB1 P2 site corresponds to a CCM, a motif found in 26% of class A GPCRs28. However, in a previous 
study, recently reported by Stevens at al.,28 CB1 was not included in the list of receptors possessing the 
CCM. Although all the interactions between cholesterol and P2 are conserved with respect to those 
detected with others CCM regions, the primary amino acid sequence of CB1 P2 site does not completely 
fulfill the CCM consensus requirements and thus has not been detected. Not far from this cholesterol 
binding region (P2 pocket) and located in the bottom part of the 7 TM-bundle, another cholesterol 
binding pocket exists (CRAC, Cholesterol Recognition Amino Acid Consensus sequence, L/V-(X)1–5-Y-
(X)1–5-R/K)22 and corresponds to P1 pocket in our model (Fig.  1a). CRAC and CCM are related by 
inversion. The existence of multiple cholesterol sites was somehow predictable since mutations in the 
CRAC region do not affect CB1 localization22.
Functional competition between cholesterol and ORG27569 was here demonstrated acting at least 
on two levels: i) as shown by functional competition assays (Figs 3,4), the binding of the two molecules 
oppositely influences affinity of CB1 for the inverse agonist AM251; ii) as shown following CB1 intracel-
lular localization, cholesterol and ORG27569 treatments compartmentalize the receptor to the axon and 
to the soma of the neuron, respectively (Figs 3,4). All together, these results enlighten a scenario where 
cholesterol, an endogenous negative modulator of CB1, and exogenous allosteric molecules compete for 
imposing specific CB1 conformations and affect its shuttling between functionally different regions of 
the neurons. In resting neurons, CB1 is localized in lipid rafts at the axons of the cells. Noteworthy, 
these rafts contain the entire endocannabinoid machinery44,45. In fact, besides cholesterol, lipid rafts are 
also enriched in i) beta2–arrestin ii) G-proteins, iii) anandamide45–47. Accordingly, in vitro experiments 
demonstrated that G-protein coupling happens at the lipid rafts48,49. As expected, agonist binding to CB1 
induces a receptor conformation change that activates G-proteins and moves the receptor to the soma, 
where it gets internalized48,49. Surprisingly, the same internalization path induced by the agonist happens 
upon ORG27569 binding. Being able to control the lateral diffusion of the receptor, ORG27569 takes 
away CB1 from its endogenous regulation, controlling its function44.
Despite our computational analysis points to explain the experimentally observed functional com-
petition between ORG27569 and cholesterol with them competing for the same site, we cannot firmly 
exclude this not being the case for CB1. Indeed, it is equally plausible that cholesterol could bind to the 
receptor at sites different from P2 and that it rather influences CB1 sensitivity to ORG27569 by changing 
the overall conformation of the receptor or affecting non-specific lipid-protein interactions. Noteworthy, 
these different effects of cholesterol are not mutual excluding and they can be all existing and partic-
ipating to the mechanism underpinning functional competition between the two allosteric molecules. 
In favour of the existence of Cholesterol/ORG27569 competition for the same CCM argues the effect 
of the F8.54A mutation (CRAC, H8, Fig.  1a), that, in our hands, generates a receptor more sensitive to 
ORG27569. Indeed, mutation of a bulky aromatic residue (Phe) with a small lipophilic one (Ala) and/
or the displacement of a bound cholesterol molecule possible consequence of such mutation, would 
facilitate conformational changes induced by ORG27569. By imposing TM2-4 packing, cholesterol would 
have an opposite effect with respect to ORG27569, which drifts these helices apart (Fig. 2c–h).
Although many conformational, pharmacological and signaling features of GPCRs have been exten-
sively studied, many aspects related to their interaction with membrane lipids are just beginning to be 
addressed. The knowledge that more than one site for cholesterol binding exist, on one hand, and the 
discovery of the exact locations of those pockets, on the other, will surely help to better characterize the 
precise mechanism of cholesterol modulation in GPCRs, which still remains partially hidden. Herein we 
demonstrated that P2 is druggable, surely in CB1 and likely in others GPCRs, by exogenous ligands albeit 
structurally unrelated to cholesterol. Indeed, if cholesterol would target the same binding ORG27569 
site, the two molecules would address the pocket in a highly different way. This finding suggests that the 
CCM sites of any GPCRs can be in principle targeted to obtain strong, selective, novel, allosteric mod-
ulators depending on the conservation among different GPCRs of the residues engaged. ORG27569 is 
an amazing example being able to distinguish even between highly related CB1 and CB2 receptors. The 
deep comprehension of the lipid effect/roles on 7TM bundle receptors surely represents one of the major 
challenges we have still to face in the GPCRs field. Efforts in this direction would enhance significantly 
our ability to design efficacious, useful and probably safer therapeutic agents.
Methods
Reagents. Salt and Organic solvents were from Sigma Aldrich (U.S.A.), Applichem (Germany) 
and Carlo Erba (Italy). FITC and Texas Red coniugated monoclonal and polyclonal secondary 
antibodies were from Sigma Aldrich (U.S.A). T1117 (Tocrifluor) (N-(Piperidin-1-yl)-5-(4-(4-(3- 
(5-carboxamido-tetramethylrhodaminyl)-propyl))phenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H- 
pyrazole-3-carboxamide), AM251 (N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4- 
methyl-1H-pyrazole-3-carboxamide) were from TOCRIS Bioscience. T1117 and AM251 were reconstituted 
in EtOH and diluted in PBS to 0.010 mM and 1.08 mM, respectively. ORG27569 (5-Chloro-3- 
ethyl-N-[2-[4-(1-piperidinyl)phenyl]ethyl-1H-indole-2-carboxamide) was reconstituted 10 mM in DMSO. 
PBS tablets were from Fluka.
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Cell Cultures and DNA transfection. HuH7, HEK293 cells were cultured in DMEM supplemented 
with 10% FBS. SHSY-5Y50 were cultured in DMEM/F12 medium supplemented with 10% FBS and non 
essential amminoacids. All cultures were grown in an atmosphere of 5% CO2 at 37 °C. Freshly defrost 
cells were used for the transfection experiments. After a maximum of 7 days in culture cell were splitted 
the day before the experiment to gain a plate at 20–30% confluence. Poliethylenimmine (PEI) in water 
(1 μ g/μ l) was used as transfecting agent. Briefly 4 μ g of DNA were mixed with 10 μ g of PEI in 150 mM 
NaCl to be then added after 30 minutes of incubation to a 10 cm dish of cells in complete fresh medium.
Mutagenesis. cDNA coding for the full length human CB1 (NM_016083) or rat 3xFLAG-CB1-GFP 
(kindly provided by professor Zsolt Lenkei ) cloned in pcDNA3.1 (Invitrogen) was used as template 
for the PCR mutagenesis. 2 Units PFU Polymerase (Promega) was supplemented with 50 ng of template 
cDNA, 125 ng of primers, 200 μ M of each dNTP according manufacturer instructions. After 1 minutes of 
denaturation at 95 °C , 18 PCR cycles (30 seconds at 95 °C, 1 minutes at 55 °C, 10 minutes at 68 °C) were 
performed. After the reaction, samples were digested with the restriction enzyme DpnI (BioLabs) for 
1 hour at 37 °C and transformed in DH5α competent cells. The sequence of the mutants were confirmed 
by sequencing of the DNA. The Upstream (up) and downstream (dw) primers used to introduce the 
indicated single amminoacidic sustituitions are listed in Supplementary Methods.
Membrane preparation from cultured cells. Cells were harvested 48 hours after the transfection 
and centrifuged for 5 minutes at 800 × g, resuspended in cold PBS, and repelleted again. Cell pellet were 
dounced 20 times in a Teflon dounce. Homogenates were centrifuged for 5 minutes at 1,000 × g (4 °C) 
to remove nuclei, cell debris and unbroken cells. The resulting was centrifuged at 20,000 × g to obtain a 
membrane fraction used for the fluorescence experiments.
Membranes preparation from Rat Brain. Adult (300–400 g), male Sprague-Dawley rats (kindly 
provided by Prof. Sorrentino and Prof. Ialenti, Faculty of Pharmacy, Naples, Italy) were killed by decap-
itation. The brains were rapidly removed and chilled in ice-cold PBS. Each organ was disrupted in 20 ml 
of cold PBS using a Teflon dounce (20 passages). The homogenates were centrifuged at 1,000 × g (4 °C) 
for 30 minutes to remove cell debris and unbroken tissues. The supernatant was centrifuged at 20,000 × g 
to and the resulting pellet frozen on solid CO2.
ORG27569 treatment. Membranes Homogenates were incubated with the indicated concentration 
of ORG27569 before being processed for fluorescence binding measurement. Cell in culture were incu-
bated with 3 μ M ORG27569 for the indicated amount of time to be then fixed and processed for immu-
nofluorescence as described below.
MβD treatment and cholesterol replenishment. Membrane Homogenates were incubated with 
10 mM Mβ D (Sigma) for 15 minutes before being processed for fluorescence binding measurement. When 
indicated soluble cholesterol (1 mM) was added to the membranes for further 15 minutes. Cultured Cells 
were incubated with 10 mM Mβ D (Sigma) for 15 minutes dissolved in PBS 0,1% BSA. When indicated 
soluble cholesterol (0,5–1 mM dissolved by sonication in PBS 0,1% BSA) was added to the cell after Mβ D. 
To determine the rate of cholesterol depletion or addition, we measured cellular cholesterol levels by a 
colorimetric assay (cholesterol/cholesteryl ester quantification; Calbiochem, La Jolla, CA) according to 
the manufacturer’s instructions. Following cholesterol addition, membranes did re-uptake amounts of 
cholesterol ranging from 50 to 70% of total cellular cholesterol.
T1117 Fluorescent measurement. Binding to T1117 was measured as previously described (Bruno 
et al., 2014)32. See Supplementary Methods for details.
Immunofluorescence. HuH7 and SHSY-5Y growing on glass coverslips were fixed in 4% 
Formaldehyde dissolved in PBS for 30 minutes. Formaldehyde was quenched by incubating the cov-
erslips for 30 minutes in 0,1M Glycine dissolved in PBS. Cells were permeabilized in 0,1% TritonX100 
for 10 minutes at RT to be then incubated with primary and secondary antibody diluted in PBS for 
1 hour and 30 minutes, respectively. In order to measure the ratio between levels of PM and intracellu-
lar 3xFLAG-CB1-GFP protein forms, cells were incubated after fixation without permeabilization with 
a rabbit polyclonal anti-FLAG antibody followed by a Texas-Red coniugated secondary antibody. The 
immunofluorescence intensity in the Texas-Red channel (depending only on the PM localized CB1) 
was measured using NIH ImageJ Biophotonic programs and normalized to one of the GFP channel 
(depending on the total CB1-GFP expression, PM + intracellular). For each transfection, 20 cells were 
considered for quantification. The results are given as mean + /− s.d.m. The following dilutions were 
used: polyclonal antiCB1 (Santa Cruz) 1:50, polyclonal antiCB2 1:50 (Santa Cruz), Texas-Red anti-rabbit 
(Sigma) 1:400. Immunfluorescence images were taken by a Leica DFC320 video-camera (Leica, Milan, 
Italy) connected to a Leica DMRB microscope equipped with a 100 X objective and the Image J Software 
(National Institutes of Health, Bethesda, MD) was used for analysis.
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CB1 immunoisolation from cultured cells and Proteinase K digestion. Cells transiently express-
ing rat CB1-GFP were lysed in B-Buffer (Hepes K-OH 50 mM, 150 mM NaCl, 1% Tryton X-100 sup-
plemented with Protease Inhibitors). Lysates were centrifuged at 14.000 rpm to remove cell debris and 
unbroken cells. Clarified lysates were incubated with the primary antibody (over night, 4 °C) followed by 
Protein-A coupled Sepharose (45 min 4 °C). Samples were extensively washed in B-Buffer to be then run 
on SDS-PAGE. Samples were in gel digested with Proteinase K (100 ng/μ l in 50 mM Hepes buffer, pH 7.8 
supplementaed with 1 mM CaCl2). 20 μ l of the digestion were processed for LC/MS.
HPLC/MS. All samples were analyzed by analytical HPLC/MS (Agilent 1200 series HPLC sys-
tem, Agilent 1260 UV-Vis detector Infinity and Agilent Quadrupole 6110 LC/MS) equipped with a 
C18-bounded analytical reverse-phase HPLC column (Vydac 218TP104, 4.6 × 250 mm) using a gradient 
elution (10 to 90% acetonitrile in water (0.1% TFA) over 20 min; flow rate = 1.0 mL/min.
LC/MS Spectra Analysis. LC/MS spectra were analyzed with MetAlign with the following setting 
[Mass resolution/BIN (nominal mass mode, 0,65), Peak slope factor (5 × noise), Peak Threshold factor 
(5 × noise), Peak Threshold Abs value (150), Average peak width (3 scans), Autoscaling on total signal, 
Tuning alignment (preAlign Processing Iterative, Mass peak selection set on Min Factor (5 × noise)]. 
Amplitudes of masses coming from treated and untreated samples were compared to identify mass exclu-
sively present in each of the sample. Masses were assigned with Mascot (MatrixScience). Samples con-
taining either Proteinase K, Protein Sepharose or antibody were run as control.
Computational Protocol. Homology model. The CB1 model was built as previously reported by 
us32, (Supplementary Table 1 and 2 and Supplementary Fig. S1 and S2). For details see Supplemental 
Materials.
Generation of the initial CB1-membrane complex and MD simulations setting. Experimental evidences 
support that palmitoylation at position C415 is fundamental for proper CB1 functionality36. Therefore, 
the refined CB1 model was palmitoylated at position C415, and the first N-terminal (S87) and the last 
C-terminal (E416) residues were capped with ACE and NME respectively. The generated model was 
embedded in an explicit POPC/Cholesterol (2:1) bilayer, applying a protocol earlier described51.
Molecular dynamics (MD) simulations were performed using NAMD2.9 software and using the 
Amber99SBildn and lipid11 as force field, atom type and parameters for the palmitoyl molecule were 
retrieved from lipid11 and gaff force field (for the acyl chain, the carbonyl group and for the thioester 
bond, respectively). For details see Supplementary Informations.
Consensus Pocket Prediction and Mutant Selections. The refined 3D model and the relaxed structure 
(after 50 ns of MD simulations) of the CB1 receptor were used to identify the ORG27569 binding site. 
We decided to employ three well-established algorithms: (i) FTMAP52, (ii) PocketFinder53, and (iii) 
Q-SiteFinder54. For each algorithm 10 druggable pockets were considered (Supplementary Fig. S3 and 
S4). Mutants were selected according to the following criteria: (i) since ORG27569 selectively bind 
CB123,24 only the pockets showing great sequence diversity with respect to CB2 sequence were take into 
account (Supplementary Fig. S4); (ii) when possible (CB1-CB2% ID = 42.50) only non conservative muta-
tion were considered (i.e. His to Leu); (iii) in the attempt to avoid mutation leading to non-functional 
mutant receptors CB1 amino acids were mutated in the corresponding CB2 residues and not in Ala 
(Supplementary Fig. S4).
Docking Studies. The refined CB1 receptor (50 ns) was used to carry out docking studies. ORG27569 
was built using the fragment builder tool of Maestro9.1 (See Supplementary Methods for details).
MD Simulations of CB1wt, CB1wt-ORG27569 bound and CB1-(H2.41L)-ORG27569 systems. MD simula-
tions of the CB1wt, CB1wt-ORG27569 and CB1-(H2.41L)-ORG27569 complexes were conducted as previ-
ously described for 1 μ s for each system (For details see Supplementary Methods section).
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